|Bid||78.99 x 900|
|Ask||79.30 x 900|
|Day's range||77.78 - 79.78|
|52-week range||68.44 - 91.40|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||28.04|
|Forward dividend & yield||2.76 (3.50%)|
|Ex-dividend date||14 Dec 2021|
|1y target est||N/A|
Yahoo Finance's Anjalee Khemlani details the record-breaking daily COVID-19 deaths as the Omicron wave continues and the beginning of Pfizer and BioNTech's clinical trial for an Omicron vaccine.
Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.
The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.